EffRx Pharmaceuticals SA is proud to announce that it will attend the upcoming medical meeting bisphosphonates2019 – Celebrating 50 years, taking place 15-17^th of July 2019 in Sheffield, UK. The year 2019 marks 50 years since the first publication on the biological effects of the bisphosphonates. The meeting which focuses 100% on bisphosphonates will review developments over the past 50 years, discuss our current understanding and look at what the future may hold.

EffRx Pharmaceuticals SA is also pleased to inform that new safety data on Binosto^® will be presented at the Bisphosphonates2019 medical meeting. The data will be presented as a poster and oral snap presentation titled “Upper Gastrointestinal Safety with the Buffered Solution of Alendronate 70 mg: 6 Years of Post-Marketing Experience” authored by B. Cortet, P. Fardellone, L. Zakin, E. Fink Eriksen on Monday, 15^th of July 2019, at 12:55 pm (poster #40).

The authors of the new Binosto^® safety data conclude that Binosto^® is associated with a lower frequency of upper gastrointestinal adverse reactions than reported for alendronate tablets and that it is a well-tolerated oral bisphosphonate for the management of osteoporosis.

“The safety data, after 6 years of post-marketing experience, reinforce that Binosto^® is a well-tolerated oral bisphosphonate for the management of osteoporosis,” says Dr Lorraine Zakin, Medical Affairs Director at EffRx Pharmaceuticals.

EffRx looks forward to seeing you at the Bisphosphonates2019 in Sheffield!

About EffRx Pharmaceuticals SA

EffRx Pharmaceuticals SA is a commercial-stage functionally integrated pharmaceutical company, based in Switzerland, that develops and commercializes niche & orphan medicines in Europe. EffRx aims to be the preferred accelerator for late clinical & regulatory development, approval, valorization of niche & orphan medicines in Europe and Switzerland.

About Binosto^®/Steovess^®

Our lead commercialized product, Binosto^® is indicated for the treatment of osteoporosis. Binosto^® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of postmenopausal osteoporosis. It reduces the risk of hip, spine, and non-spine fractures.¹ The buffered solution with high acid-neutralizing capacity minimizes the risk of exposing the esophagus (in case of reflux) and the stomach to acidified alendronate.^2,3 Binosto^® is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus. Binosto^® has the potential to improve adherence to therapy⁴, thereby decreasing the risk of disabling fractures.

Disclaimer: Statements made here are according the approved Binosto Summary of Product Characteristics in Europe. Please refer to the Binosto^®/Steovess^® prescribing information and approved indications, contraindications, and warnings in your country.

References:

1. Black DM et al. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
2. Binosto Summary of Product Characteristics. 2017.
3. Hodges LA et al. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate. Int J Pharm 2012;432:57-62.
4. Giusti A et al. Persistence with the buffered solution of alendronate 70 mg: prospective observational study. Osteoporos Int 2018;29(S1):S431.
   
   

Media Contact: Pamela Saredi, psaredi@effrx.com